S
Scipher Medicine
Bringing precision medicine to complex diseases through the power of network medicine
About Scipher Medicine
Scipher Medicine is a healthcare technology startup that operates in the pharmaceutical and medical testing market. The company's primary focus is to reduce the $552 billion wasted annually on ineffective drug prescriptions. It does this by using a patient's individual molecular data to determine the most effective therapy from the onset. This not only improves patient outcomes but also saves money for both healthcare providers and payers.
Read full description
Scipher Medicine's business model revolves around a unique blood-based molecular signature test. This test identifies a patient's unique disease biology, which helps determine the most effective drug for the patient's condition. This allows healthcare providers and payers to make more informed therapy decisions, increasing the likelihood of reaching treatment goals.
In addition to this, Scipher Medicine also collects clinico-genomic data from tested patients. This data is then analyzed by the company's AI platform to gain novel insights into autoimmune diseases. These insights can reveal new drug targets specific to biologically similar patient populations, which can lead to the development of more effective drugs.
Scipher Medicine's clients primarily include healthcare providers and payers, who benefit from the cost savings and improved patient outcomes that the company's technology offers. The company generates revenue through the sale of its molecular signature tests and the valuable data it collects and analyzes.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Waltham, United States
- Employees
- 56
- Open positions
- None listed
- Dealroom signal
- 67.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Drug Development, Core AI, Precision Medicine, Spinout, Biotech and Pharma, AI Drug Discovery
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Feb 2022 | $110M | $440M | Cowen Group · Khosla Ventures · Monashee Investment Management · Laurion Capital Management | ↗ |
| SERIES COther financing | Mar 2021 | $82M | $328M | Khosla Ventures · Alumni Ventures · aMoon Fund · Northpond Ventures | — |
Growth signals
Latest recorded traffic for Scipher Medicine is 3.2K monthly website visits, up 113.3% over the last three months. Scipher Medicine's team declined 8.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chemomab TherapeuticsTel Aviv-Yafo, IsraelClinical-stage biotech company focusing on the discovery and development of innovative therapeutics
$10Mvaluation
CrossBridge HealthRadnor Township, United StatesUsing data to improve patient outcomes and save money on healthcare costs
$6.7Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Khosla Ventures
Northpond Ventures
Green D Ventures
Alumni Ventures
Optum Ventures
Series B and later7 investors entered at this stage
aMoon Fund
Echo Health Ventures
Cowen Group
Monashee Investment Management
Laurion Capital Management
Neuberger Berman
Hitachi Ventures
Other known investors1 additional known investor
Northeastern University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Scipher Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scipher Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.